The Third RabMAb® Advantage for Immunohistochemistry

RabMAb® antibodies are suitable for challenging applications like immunohistochemistry (IHC) on FFPE tissues because they provide better sensitivity without any loss of specificity.

RabMAb rabbit monoclonal antibodies enable higher working dilutions — that is, 5X–10X on average — and can be applied with numerous tissue fixations, like FFPE at a minimal level of pretreatment. These antibodies are invariably tested on human lymphoid/lymphoma tissue microarray (TMA) built with FFPE tissues for immunohistochemical staining. When applied along with a mouse monoclonal, dual staining can also be performed with two monoclonal antibodies for high-quality double staining on the same sample of tissue.

The custom services team at Abcam has a proven record of success in producing custom rabbit monoclonal antibodies that have improved sensitivity, rendering them “best in class” for IHC.

The rabbit monoclonal antibody against ERCC1 (ab129267) worked beautifully on the first try of our IHC experiments. Our lab works with mice that have either knocked-out ERCC1 or a lower expression of ERCC1 (25% expression). There is a clear difference between the expression of a WT, KO, and lower expression ERCC1 in all tissues.

Researcher, The Scripps Research Institute

HER2 RabMAb Antibody IHC Comparison

A HER2/ErbB2 RabMAb antibody is compared with top commercially available HER2/ErbB2 rabbit polyclonal (vendor A) as well as mouse monoclonal (vendor B) antibodies on FFPE human breast carcinoma tissue. For each case, Abcam’s proposed IHC protocol and dilution factor were applied, and the antibody concentrations applied are given below the images for individual stains.

HER2 RabMAb antibody (3 ng/mL)

HER2 RabMAb antibody (3 ng/mL)

Rabbit polyclonal antibody (vendor A) (20 ng/mL)

Rabbit polyclonal antibody (vendor A) (20 ng/mL)

Mouse monoclonal antibody (vendor B) (30 ng/mL)

Mouse monoclonal antibody (vendor B) (30 ng/mL)

Examples of Double Staining Using RabMAb Antibodies

CK8 and Ki67

IHC on human urinary bladder cancer tissue using anti-CK8 RabMAb (ab53280) with Fast Red and anti-Ki67 Mouse MAb with DAB.

IHC on human urinary bladder cancer tissue using anti-CK8 RabMAb (ab53280) with Fast Red and anti-Ki67 Mouse MAb with DAB.

HER2/ErbB2 and ER Alpha

IHC on human breast cancer tissue using anti-HER2/ErbB2 RabMAb (ab134182) with Fast Red and anti-ER Alpha Mouse MAb with DAB.

IHC on human breast cancer tissue using anti-HER2/ErbB2 RabMAb (ab134182) with Fast Red and anti-ER Alpha Mouse MAb with DAB.

AIF and p53

IHC on human prostate cancer tissue using anti-AIF RabMAb (ab32516) with Fast Red and anti-p53 Mouse MAb with DAB.

IHC on human prostate cancer tissue using anti-AIF RabMAb (ab32516) with Fast Red and anti-p53 Mouse MAb with DAB.

About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: May 2, 2019 at 9:36 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abcam. (2019, May 02). The Third RabMAb® Advantage for Immunohistochemistry. News-Medical. Retrieved on December 05, 2019 from https://www.news-medical.net/whitepaper/20190502/The-Third-RabMAb-Advantage-for-Immunohistochemistry.aspx.

  • MLA

    Abcam. "The Third RabMAb® Advantage for Immunohistochemistry". News-Medical. 05 December 2019. <https://www.news-medical.net/whitepaper/20190502/The-Third-RabMAb-Advantage-for-Immunohistochemistry.aspx>.

  • Chicago

    Abcam. "The Third RabMAb® Advantage for Immunohistochemistry". News-Medical. https://www.news-medical.net/whitepaper/20190502/The-Third-RabMAb-Advantage-for-Immunohistochemistry.aspx. (accessed December 05, 2019).

  • Harvard

    Abcam. 2019. The Third RabMAb® Advantage for Immunohistochemistry. News-Medical, viewed 05 December 2019, https://www.news-medical.net/whitepaper/20190502/The-Third-RabMAb-Advantage-for-Immunohistochemistry.aspx.

Other White Papers by this Supplier